PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |diabetes |
| Sentences | 529 |
| PubMedID- 24379686 | Dyslipidemia, an established risk factor for cardiovascular disease, is common in patients with type 2 diabetes, affecting almost 50% of this population. |
| PubMedID- 25527522 | Conclusions: in our series, type 2 diabetes mellitus patients with cardiovascular disease at baseline present with an increased risk of developing diabetic peripheral neuropathy at 10 years of follow-up. |
| PubMedID- 24800002 | Obesity during childhood has been established to be strongly associated with that in adulthood and also with several chronic diseases such as diabetes, some types of cancer and cardiovascular diseases [1–6]. |
| PubMedID- 21398276 | Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. |
| PubMedID- 25014552 | diabetes is strongly associated with cardiovascular disease, but the mechanisms, structural and biomechanical consequences of aberrant blood vessel remodelling remain poorly defined. |
| PubMedID- 23320535 | The hazard ratios for the relative risk of death from cardiovascular disease with respect to diabetes were estimated (table 3). |
| PubMedID- 23236389 | Morbidity from diabetes is a consequence of both microvascular disease (retinopathy, nephropathy, and neuropathy) and macrovascular disease (atherosclerosis), and therefore organ dysfunctions are often inter-related. |
| PubMedID- 23593110 | The following risk categories that modify ldl-c goals were generated: less than 160 mg/dl (4.14 mmol/l) if low risk (0–1 risk factor), less than 130 mg/dl (3.37 mmol/l) if moderate risk (≥2 risk factors and framingham risk score 10–20%), less than 100 mg/dl (2.59 mmol/l) if high risk (cad or cad risk equivalents) and less than 70 mg/dl (1.81 mmol/l) for very high-risk patients (those who have had a recent heart attack, or have cardiovascular disease combined with diabetes). |
| PubMedID- 20929995 | Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (glp-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. |
| PubMedID- 22293888 | As some studies were designed to prospectively evaluate ms and cardiovascular disease, individuals with diabetes or cardiovascular diseases were excluded from samples [33,35,36]. |
| PubMedID- 26583056 | The pathological state is defined as metabolic syndrome, which is a risk factor for diabetes and the complications of diabetic cardiac-cerebral vascular disease. |
| PubMedID- 26385225 | Two points were assigned for recent hospitalization or intensive care unit (icu) admission and one point was assigned for each of the following: age <30 or >79 years, prior intravenous (iv) antibiotics in last 30 days, dementia, cardiovascular disease, female with diabetes, or recent exposure to a nursing home, long-term care facility, or skilled nursing facility. |
| PubMedID- 21318583 | The underlying causes for this disconnect are not known, but may be related to species differences, bleeding time versus spontaneous bleeding, vascular bed differences, and the fact that unlike animal bleeding models, the appraise-2 patients had the highest tendency to bleed due to advanced age, diabetes, complications of cardiovascular disease, other comorbidities and the additive hazards of combination antiplatelet treatment. |
| PubMedID- 23604419 | The great burden of cardiovascular disease (cvd) in patients with type 2 diabetes is well known. |
| PubMedID- 22853195 | Although food restriction is a standard therapy in type ii diabetic patients, no long-term large-scale study of intentional weight loss has been adequately powered to examine cardiovascular disease end points in patients with diabetes [10]. |
| PubMedID- 24595856 | Aims/hypothesis: obesity and diabetes increase the risk of developing cardiovascular diseases and heart failure. |
| PubMedID- 24905298 | General significance: this strategy might prove clinically relevant in preventing the development and/or retarding the progression of diabetes associated with vascular diseases. |
| PubMedID- 25285121 | He did not have diabetes or history of peripheral vascular disease. |
| PubMedID- 26240497 | Several studies have reported that cardiovascular risks factors, including smoking, diabetes, and a history of cardiovascular disease, are also related to hearing loss (578910). |
| PubMedID- 24512719 | The deleterious effects of glucotoxicity have an important role in the progressive impairment of insulin secretion and sensitivity, two major factors in the pathogenesis of type 2 diabetes, which can lead to future microvascular diseases or others complications [1]. |
| PubMedID- 22672997 | Cadjusted for age (categorical), hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein cholesterol, abdominal obesity, diabetes, hypertension, family history of cardiovascular disease, menopause, current smoking, education, and weight. |
| PubMedID- 26419903 | Similarly, the findings of collaborative meta-analysis of 102 prospective studies reported a twofold higher risk for a wide range of vascular diseases in people with diabetes in comparison with those without diabetes mellitus [27]. |
| PubMedID- 24251228 | It is known that diabetes doubles the risk of various vascular diseases. |
| PubMedID- 23417760 | These endothelial alterations contribute to excess cardiovascular disease in diabetes, but may also play a role in the pathogenesis of diabetes, especially type 2. |
| PubMedID- 22906083 | Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary care. |
| PubMedID- 23396240 | This paper examines the usefulness of several noninvasive imaging techniques to study cardiovascular diseases in individuals with diabetes mellitus, with emphasis on nuclear cardiology, and proposes a diagnostic algorithm for detection of silent ischemia. |
| PubMedID- 21785619 | A therapeutic effect of myricetin in patients with cardiovascular diseases associated with diabetes mellitus has also been reported [1, 2]. |
| PubMedID- 26243552 | The relative risk of cardiovascular diseases in those with diabetes is approximately twice the level seen in those without diabetes.9 although glycated haemoglobin a1c (hba1c), which was integrated into the diagnostic criteria for diabetes by the american diabetes association in 2010, has been demonstrated to be associated with cardiovascular diseases in observational studies,10 evidence from randomised controlled trials is not consistent regarding hba1c reduction and macrovascular outcomes.1112 moreover, few studies have examined the association between hba1c concentrations and low-grade albuminuria, an early marker of cardiovascular diseases, or compared the associations with low-grade albuminuria among hba1c, fasting plasma glucose (fpg) and 2 h postload glucose (2 h pg). |
| PubMedID- 23730303 | Abnormal endothelial function is a salient feature of vascular disease in diabetes that is exemplified by a decrease in nitric oxide (no) synthesis or bioavailability. |
| PubMedID- 24354901 | Model 3: model 2 plus adjustment for medications (for hypertension, diabetes, and dyslipidemia), history of stroke or cardiovascular disease, daily alcohol consumption (versus infrequent/no alcohol consumption), and regular exercise (≥30 min exercise per session >2 times/week versus infrequent exercise). |
| PubMedID- 20448009 | Background: resting heart rate has been shown to predict risk of cardiovascular disease; its association with diabetes remains unclear, particularly in non-western populations. |
| PubMedID- 25466521 | The differences between relative risks of different cardiovascular diseases in patients with type 2 diabetes have implications for clinical risk assessment and trial design. |
| PubMedID- 22701470 | Functional abnormalities of the vascular endothelial lining have been shown to precede overt cardiovascular disease in patients with and without diabetes [1, 2, 6, 7]. |
| PubMedID- 22569118 | Background: although most deaths among patients with type 2 diabetes (t2d) are attributable to cardiovascular disease, modifiable cardiovascular risk factors appear to be inadequately treated in medical practice. |
| PubMedID- 20700576 | Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation (advance) trial. |
| PubMedID- 23250802 | Objective: to examine the bmi-stratified associations between diabetes and the risks of all-cause death, cardiovascular disease (cvd) death, and cancer death. |
| PubMedID- 25099744 | Objective: dyslipidemia contributes to the increased risk of cardiovascular disease in persons with type 1 diabetes (t1d). |
| PubMedID- 20804517 | Aims: to analyse the association between glycosylated haemoglobin a1c (hba1c) and cardiovascular disease (cvd) in patients with type 2 diabetes in the swedish national diabetes register (ndr). |
| PubMedID- 22711281 | Most diabetes-related complications and causes of death arise from cardiovascular disease and end-stage renal disease. |
| PubMedID- 23250799 | However, as diabetes may be associated with macrovascular disease prior to esrd, adjusting for diabetes may control for some residual confounding that may have existed in the overall model. |
| PubMedID- 22228612 | Dyslipidaemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. |
| PubMedID- 24465050 | And, would monotherapy with either or both of those drugs reduce the risk of cardiovascular disease events in patients with type 2 diabetes mellitus? |
| PubMedID- 21772665 | Diabetic cardiomyopathy entails the cardiac injury induced by diabetes independently of any vascular disease or hypertension. |
| PubMedID- 21078616 | The contribution of the hemostatic system in the development of cardiovascular disease (cvd) in patients with type 2 diabetes is not completely defined. |
| PubMedID- 26246459 | Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 21955218 | Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. |
| PubMedID- 24953607 | Aims: non-alcoholic fatty liver disease and its precursor hepatic steatosis is common in obesity and type-2 diabetes and is associated with cardiovascular disease (cvd). |
| PubMedID- 20522598 | Recent studies have suggested a potential role of the receptor for advanced glycation end products (rage) in the development of vascular disease in individuals with diabetes (1). |
| PubMedID- 21625418 | The goal for non-hdl cholesterol has been reported to be the level of ldl cholesterol plus 30 mg/dl.36 in type 2 diabetics, several characteristics such as elevated triglycerides, decreased hdl cholesterol, and elevated small dense ldl, are well-known.25 because non-hdl cholesterol reflects all apolipoprotein b-containing atherogenic lipoproteins, non-hdl cholesterol may be useful in predicting cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 21767347 | Background: the aim of the present study was to examine trends in the control of key risk factors for cardiovascular disease among adults with diagnosed diabetes in the us from 1999 to 2008. |